lenvatinib
eisai pharmaceutical
['lenva']
activity of lenvatinib in pts with refractory or metastatic t and tc, 53% as a 2nd line. orr of 33% (40% for tc) with disease control of 90% in thymoma subtypes (20% of pr). good toxicity profile. #asco22 
Medical Oncologist, Lung cancer & Thymic tumors @GustaveRoussy. PhD in Translational research  program @Hospitalclinic @UniversitatBarcelona